Deana Ferreri, PhD

A study reveals high drug survival rates for anti-TNF biosimilars in treating psoriasis and psoriatic arthritis, highlighting their long-term efficacy and safety.

SB17, a new ustekinumab biosimilar, demonstrates comparable efficacy and safety for psoriasis and psoriatic arthritis, enhancing patient experience and convenience.

Using vedolizumab first, before tumor necrosis factor-α inhibitors, improved quality-adjusted life-years in both ulcerative colitis and Crohn disease, and was less costly in ulcerative colitis, according to a real-world economic analysis from the EVOLVE study.

Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimilar's FDA approval.

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.

A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.

Increasing knowledge of mutations and signaling proteins in diffuse large B-cell lymphoma (DLBCL) offer prognostic and therapeutic advantages, according to a review of recent findings.

Special approval programs have increased FDA administrative costs (paid for mostly by user fees), and postponements of generic competition have been costly to the US healthcare system, according to a recent article in JAMA.